...
首页> 外文期刊>Regulatory Toxicology and Pharmacology: RTP >Differential analyses of major allergen proteins in wild-type rice and rice producing a fragment of anti-rotavirus antibody
【24h】

Differential analyses of major allergen proteins in wild-type rice and rice producing a fragment of anti-rotavirus antibody

机译:野生型水稻和产生抗轮状病毒抗体片段的水稻中主要过敏原蛋白的差异分析

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

To develop oral antibody therapy against rotavirus infection, we previously produced a recombinant fragment of llama heavy-chain antibody to rotavirus (ARP1) in rice seeds (MucoRice-ARP1). We intend to use a purification-free rice powder for clinical application but needed to check whether MucoRice-ARP1 had increased levels of known allergen proteins. For this purpose, we used two-dimensional fluorescence difference gel electrophoresis to compare the allergen protein levels in MucoRice-ARP1 and wild-type rice. We detected no notable differences, except in the levels of alpha-amylase/trypsin inhibitor-like family proteins. Because by this approach we could not completely separate ARP1 from the proteins of this family, we confirmed the absence of changes in the levels of these allergens by using shotgun mass spectrometry as well as immunoblot. By using immunoelectron microscopy, we also showed that RAG2, a member of the alpha-amylase/trypsin inhibitor-like protein family, was relocated from protein bodies II to the plasma membrane or cell wall in MucoRice-ARP1 seed. The relocation did not affect the level of RAG2. We demonstrated that most of the known rice allergens were not considerably upregulated by the genetic modification in MucoRice-ARP1. Our data suggest that MucoRice-ARP1 is a potentially safe oral antibody for clinical application. (C) 2016 Elsevier Inc. All rights reserved.
机译:为了开发针对轮状病毒感染的口服抗体疗法,我们先前在稻米种子(MucoRice-ARP1)中生产了针对轮状病毒(ARP1)的美洲驼重链抗体的重组片段。我们打算将无纯化的米粉用于临床,但需要检查MucoRice-ARP1是否增加了已知的过敏原蛋白水平。为此,我们使用了二维荧光差异凝胶电泳来比较MucoRice-ARP1和野生型水稻中的过敏原蛋白水平。除了α-淀粉酶/胰蛋白酶抑制剂样家族蛋白的水平外,我们没有发现任何显着差异。因为通过这种方法我们无法将ARP1与该家族的蛋白质完全分开,所以我们通过shot弹枪质谱和免疫印迹证实了这些过敏原水平没有变化。通过使用免疫电子显微镜,我们还显示,RAG2,α-淀粉酶/胰蛋白酶抑制剂样蛋白家族的成员,已从蛋白体II移至MucoRice-ARP1种子的质膜或细胞壁。迁移不会影响RAG2的水平。我们证明,大多数已知的水稻过敏原并没有通过MucoRice-ARP1中的基因修饰而明显上调。我们的数据表明MucoRice-ARP1是用于临床应用的潜在安全的口服抗体。 (C)2016 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号